NCT04919382 - Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 26, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Extensive Stage Lung Small Cell CarcinomaMetastatic Lung Small Cell CarcinomaRecurrent Lung Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

Interventions

BIOLOGICAL

Atezolizumab

Given IV

DRUG

Temozolomide

Given PO

Trial Locations (5)

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

52242

RECRUITING

University of Iowa Hospitals and Clinics, Iowa City

53705

RECRUITING

University of Wisconsin, Madison

60612

RECRUITING

University of Illinois Cancer Center, Chicago